5. Savara Inc. (NASDAQ:SVRA)
Number of Hedge Fund Holders: 36
Market Capitalization: $1.03 billion
Share Price: $4.86
Savara Inc. (NASDAQ: SVRA) sits near the midpoint of this ranking with a concentrated investment case built around MOLBREEVI, the proposed trade name for molgramostim inhalation solution. The investigational treatment targets autoimmune pulmonary alveolar proteinosis, or aPAP, a rare respiratory disease with significant unmet medical needs.
The condition involves an abnormal buildup of surfactant in the lungs’ air sacs, interfering with gas exchange. Molgramostim is designed to support the immune-cell activity needed to clear that material, addressing a biological process central to the disease.
The FDA accepted the biologics license application and assigned a November 22, 2026 target action date, according to the company’s second-quarter update. Regulatory applications were also under review in the United Kingdom and European Union.
That places regulatory execution at the center of the stock’s near-term outlook. Approval could allow the company to establish a commercial business, while the final label, launch timing, and reimbursement arrangements would influence the scale of the opportunity.
JPMorgan initiated coverage on October 7 with an Overweight rating and a $12 price target, citing the potential commercial opportunity across major markets.
Financial preparation is already underway. The company held approximately $173 million in cash, cash equivalents, and short-term investments at June 30 and was building its commercial infrastructure. Its second-quarter net loss of $40.2 million also shows that launch readiness carries costs before product revenue arrives.
Ranking rationale: Savara Inc. (NASDAQ: SVRA) ranks fifth with 36 hedge-fund holders. Its pending regulatory decision and potential entry into an underserved rare-disease market support inclusion, although the business remains heavily dependent on the outcome and commercialization of its lead program.
